4 results on '"Tykalová, Tereza"'
Search Results
2. Spoken Language Alterations can Predict Phenoconversion in Isolated Rapid Eye Movement Sleep Behavior Disorder: A Multicenter Study.
- Author
-
Šubert, Martin, Novotný, Michal, Tykalová, Tereza, Hlavnička, Jan, Dušek, Petr, Růžička, Evžen, Škrabal, Dominik, Pelletier, Amelie, Postuma, Ronald B., Montplaisir, Jacques, Gagnon, Jean‐François, Galbiati, Andrea, Ferini‐Strambi, Luigi, Marelli, Sara, St. Louis, Erik K., Timm, Paul C., Teigen, Luke N., Janzen, Annette, Oertel, Wolfgang, and Heim, Beatrice
- Subjects
RAPID eye movement sleep ,SLEEP ,AUTOMATIC speech recognition ,ORAL communication ,NATURAL language processing ,ORTHOPEDIC shoes ,ELLAGIC acid - Abstract
Objective: This study assessed the relationship between speech and language impairment and outcome in a multicenter cohort of isolated/idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD). Methods: Patients with iRBD from 7 centers speaking Czech, English, German, French, and Italian languages underwent a detailed speech assessment at baseline. Story‐tale narratives were transcribed and linguistically annotated using fully automated methods based on automatic speech recognition and natural language processing algorithms, leading to the 3 distinctive linguistic and 2 acoustic patterns of language deterioration and associated composite indexes of their overall severity. Patients were then prospectively followed and received assessments for parkinsonism or dementia during follow‐up. The Cox proportional hazard was performed to evaluate the predictive value of language patterns for phenoconversion over a follow‐up period of 5 years. Results: Of 180 patients free of parkinsonism or dementia, 156 provided follow‐up information. After a mean follow‐up of 2.7 years, 42 (26.9%) patients developed neurodegenerative disease. Patients with higher severity of linguistic abnormalities (hazard ratio [HR = 2.35]) and acoustic abnormalities (HR = 1.92) were more likely to develop a defined neurodegenerative disease, with converters having lower content richness (HR = 1.74), slower articulation rate (HR = 1.58), and prolonged pauses (HR = 1.46). Dementia‐first (n = 16) and parkinsonism‐first with mild cognitive impairment (n = 9) converters had higher severity of linguistic abnormalities than parkinsonism‐first with normal cognition converters (n = 17). Interpretation: Automated language analysis might provide a predictor of phenoconversion from iRBD into synucleinopathy subtypes with cognitive impairment, and thus can be used to stratify patients for neuroprotective trials. ANN NEUROL 2024;95:530–543 [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Speech Biomarkers in Rapid Eye Movement Sleep Behavior Disorder and Parkinson Disease
- Author
-
Rusz, Jan, primary, Hlavnička, Jan, additional, Novotný, Michal, additional, Tykalová, Tereza, additional, Pelletier, Amelie, additional, Montplaisir, Jacques, additional, Gagnon, Jean‐Francois, additional, Dušek, Petr, additional, Galbiati, Andrea, additional, Marelli, Sara, additional, Timm, Paul C., additional, Teigen, Luke N., additional, Janzen, Annette, additional, Habibi, Mahboubeh, additional, Stefani, Ambra, additional, Holzknecht, Evi, additional, Seppi, Klaus, additional, Evangelista, Elisa, additional, Rassu, Anna Laura, additional, Dauvilliers, Yves, additional, Högl, Birgit, additional, Oertel, Wolfgang, additional, St. Louis, Erik K., additional, Ferini‐Strambi, Luigi, additional, Růžička, Evžen, additional, Postuma, Ronald B., additional, and Šonka, Karel, additional
- Published
- 2021
- Full Text
- View/download PDF
4. Speech Biomarkers in Rapid Eye Movement Sleep Behavior Disorder and Parkinson Disease
- Author
-
Jacques Montplaisir, Paul C. Timm, Erik K. St. Louis, Evi Holzknecht, Petr Dusek, Klaus Seppi, Evžen Růžička, Luke N. Teigen, Tereza Tykalová, Sara Marelli, Ronald B. Postuma, Andrea Galbiati, Karel Sonka, Michal Novotný, Amélie Pelletier, Mahboubeh Habibi, Yves Dauvilliers, Annette Janzen, Wolfgang H. Oertel, Jan Rusz, Luigi Ferini-Strambi, Jan Hlavnička, Birgit Högl, Ambra Stefani, Jean Gagnon, Elisa Evangelista, Anna Laura Rassu, Rusz, Jan, Hlavnička, Jan, Novotný, Michal, Tykalová, Tereza, Pelletier, Amelie, Montplaisir, Jacque, Gagnon, Jean-Francoi, Dušek, Petr, Galbiati, Andrea, Marelli, Sara, Timm, Paul C, Teigen, Luke N, Janzen, Annette, Habibi, Mahboubeh, Stefani, Ambra, Holzknecht, Evi, Seppi, Klau, Evangelista, Elisa, Rassu, Anna Laura, Dauvilliers, Yve, Högl, Birgit, Oertel, Wolfgang, St Louis, Erik K, Ferini-Strambi, Luigi, Růžička, Evžen, Postuma, Ronald B, Šonka, Karel, Czech Technical University in Prague (CTU), First Faculty of Medicine Charles University [Prague], Hôpital du Sacré-Coeur de Montréal, McGill University Health Center [Montreal] (MUHC), Universita Vita Salute San Raffaele = Vita-Salute San Raffaele University [Milan, Italie] (UniSR), Mayo Clinic [Rochester], Philipps Universität Marburg = Philipps University of Marburg, Innsbruck Medical University = Medizinische Universität Innsbruck (IMU), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut des Neurosciences de Montpellier (INM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), and Retiveau, Nolwenn
- Subjects
0301 basic medicine ,Male ,Disease ,REM Sleep Behavior Disorder ,Audiology ,Behavior disorder ,Dysarthria ,MESH: Aged, 80 and over ,0302 clinical medicine ,Research Articles ,MESH: Aged ,Aged, 80 and over ,MESH: Middle Aged ,MESH: Speech ,Parkinsonism ,Parkinson Disease ,Middle Aged ,Europe ,Neurology ,Disease Progression ,Biomarker (medicine) ,MESH: Disease Progression ,[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,Female ,medicine.symptom ,Research Article ,medicine.medical_specialty ,Rapid eye movement sleep ,Prodromal Symptoms ,REM sleep behavior disorder ,03 medical and health sciences ,medicine ,Humans ,Speech ,[SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,MESH: Prodromal Symptoms ,Aged ,MESH: Humans ,business.industry ,Disease progression ,medicine.disease ,MESH: Male ,030104 developmental biology ,MESH: REM Sleep Behavior Disorder ,MESH: Biomarkers ,MESH: Europe ,Neurology (clinical) ,business ,MESH: Female ,MESH: Parkinson Disease ,030217 neurology & neurosurgery ,Biomarkers - Abstract
International audience; Objective: This multilanguage study used simple speech recording and high-end pattern analysis to provide sensitive and reliable noninvasive biomarkers of prodromal versus manifest α-synucleinopathy in patients with idiopathic rapid eye movement sleep behavior disorder (iRBD) and early-stage Parkinson disease (PD).Methods: We performed a multicenter study across the Czech, English, German, French, and Italian languages at 7 centers in Europe and North America. A total of 448 participants (337 males), including 150 with iRBD (mean duration of iRBD across language groups 0.5-3.4 years), 149 with PD (mean duration of disease across language groups 1.7-2.5 years), and 149 healthy controls were recorded; 350 of the participants completed the 12-month follow-up. We developed a fully automated acoustic quantitative assessment approach for the 7 distinctive patterns of hypokinetic dysarthria.Results: No differences in language that impacted clinical parkinsonian phenotypes were found. Compared with the controls, we found significant abnormalities of an overall acoustic speech severity measure via composite dysarthria index for both iRBD (p = 0.002) and PD (p < 0.001). However, only PD (p < 0.001) was perceptually distinct in a blinded subjective analysis. We found significant group differences between PD and controls for monopitch (p < 0.001), prolonged pauses (p < 0.001), and imprecise consonants (p = 0.03); only monopitch was able to differentiate iRBD patients from controls (p = 0.004). At the 12-month follow-up, a slight progression of overall acoustic speech impairment was noted for the iRBD (p = 0.04) and PD (p = 0.03) groups.Interpretation: Automated speech analysis might provide a useful additional biomarker of parkinsonism for the assessment of disease progression and therapeutic interventions. ANN NEUROL 2021;90:62-75.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.